IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25” March 12, 2025 Read More »
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results” March 10, 2025 Read More »
IGC Pharma Expands AI Platform with Advanced Diagnostic Model for Alzheimer’s and Dementia Detection March 4, 2025 Read More »
IGC Pharma Expands Holiby™ Product Line with ‘Longevity’ and ‘Renew’ – Targeting the Multi-Billion-Dollar Anti-Aging Market February 20, 2025 Read More »
IGC Pharma Expands into $75 Billion Wellness Market with the Launch of Holiby™ February 11, 2025 Read More »
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer’s Disease January 28, 2025 Read More »
IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor January 21, 2025 Read More »
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets January 13, 2025 Read More »
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer’s Agitation “CALMA” and Expands Recruitment Strategy January 8, 2025 Read More »
